Supplementary Material

**Biofilm-induced type 2 innate immunity in a cystic fibrosis model of *Pseudomonas aeruginosa***

**Kenny Bielen1,2, Bart ‘S Jongers1, Jan Boddaert1, Tom K Raju1, Christine Lammens2, Surbhi Malhotra-Kumar2, Philippe G Jorens3, Herman Goossens2, Samir Kumar-Singh1,2\***

**\*Correspondence:**

Corresponding author mailing address: Prof. dr. S. Kumar-Singh, MD, PhD, Molecular Pathology Group, Laboratory of Cell Biology and Histology, Faculty of Medicine and Health Sciences – D.T.1.32, University of Antwerp, Universiteitsplein1, B-2610 Wilrijk, Belgium. Phone: 32-3-265-3329. E-mail: samir.kumarsingh@uantwerpen.be

**Supplementary Table 1.** Clinical scoring scheme used for monitoring disease progression in pneumonia models where animals can have a maximum score of 28 points.

|  |  |  |
| --- | --- | --- |
| **Stage disease development** | **Description of clinical symptoms** | **Points** |
| **Stage 1: early signs of pneumonia** | Avoidance | 1 |
| Loss of appetite | 1 |
| Fever | 1 |
| Piloerection | 1 |
| Rapid breathing | 1 |
| Ruffled fur | 1 |
| **Stage 2: signs of severe inflammation and infection** | Labored breathing | 2 |
| Hunched posture  | 2 |
| Wheezing, small cough | 2 |
| Lethargy | 2 |
| Periorbital congestion | 2 |
| **Stage 3: signs of compromised lung function** | Very shallow breathing | 3 |
| Prostrate, not reactive | 3 |
| Gasping  | 3 |
| Cyanosis at the tip of tail and feet | 3 |